David W Hawman

Mar 27, 2024 | nature.com | Vanessa Monteil |Shane Wright |Sofia Appelberg |Hyesoo Kwon |Ioannis Pittarokoilis |Georg Michlits | +11 more

AbstractClimate change and population densities accelerated transmission of highly pathogenic viruses to humans, including the Crimean–Congo haemorrhagic fever virus (CCHFV). Here we report that the Low Density Lipoprotein Receptor (LDLR) is a critical receptor for CCHFV cell entry, playing a vital role in CCHFV infection in cell culture and blood vessel organoids.

Apr 19, 2023 | journals.plos.org | Megan O’Connor |David W Hawman |Rocky Mountain Laboratories |PLOS Pathogens

The repRNA-CoV2S vaccine affords durable protection from SARS-CoV-2 induced clinical disease and pathologyWe next evaluated the ability of the vaccine to protect from clinical disease and lung pathology. Animals were comprehensively evaluated by trained research staff for evidence of disease including reduced appetite, lethargy, respiratory distress, and general appearance. The most common clinical observations among unvaccinated animals were lethargy, abnormal respiration, and nasal discharge.

Mar 14, 2023 | nature.com | David W Hawman |Heinz Feldmann

AbstractCrimean–Congo haemorrhagic fever (CCHF) is a severe tick-borne illness with a wide geographical distribution and case fatality rates of 30% or higher. Caused by infection with the CCHF virus (CCHFV), cases are reported throughout Africa, the Middle East, Asia and southern and eastern Europe. The expanding range of the Hyalomma tick vector is placing new populations at risk for CCHF, and no licensed vaccines or specific antivirals exist to treat CCHF.